DE3240044A1 - Verwendung von 17(alpha)-acyloxy-6-methylpregna-4,6-dien-3,20-dionen zur bekaempfung von brustkrebs - Google Patents

Verwendung von 17(alpha)-acyloxy-6-methylpregna-4,6-dien-3,20-dionen zur bekaempfung von brustkrebs

Info

Publication number
DE3240044A1
DE3240044A1 DE19823240044 DE3240044A DE3240044A1 DE 3240044 A1 DE3240044 A1 DE 3240044A1 DE 19823240044 DE19823240044 DE 19823240044 DE 3240044 A DE3240044 A DE 3240044A DE 3240044 A1 DE3240044 A1 DE 3240044A1
Authority
DE
Germany
Prior art keywords
acyloxy
breast cancer
treatment
methylpregna
megestrol acetate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
DE19823240044
Other languages
German (de)
English (en)
Inventor
Merritt R. 46032 Carmel Ind. Callantine
Martin O. 47711 Evansville Ind. Greaney
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US05/719,558 priority Critical patent/US4370321A/en
Priority to AU89358/82A priority patent/AU558559B2/en
Priority to CA000413579A priority patent/CA1205744A/en
Priority to FR8217377A priority patent/FR2534476B1/fr
Priority to JP57182210A priority patent/JPS5973523A/ja
Application filed by Bristol Myers Co filed Critical Bristol Myers Co
Priority to BE0/209365A priority patent/BE894860A/fr
Priority to DE19823240044 priority patent/DE3240044A1/de
Priority to GB08231069A priority patent/GB2129297B/en
Publication of DE3240044A1 publication Critical patent/DE3240044A1/de
Priority to MY8231069A priority patent/MY8800128A/xx
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
DE19823240044 1976-09-01 1982-10-28 Verwendung von 17(alpha)-acyloxy-6-methylpregna-4,6-dien-3,20-dionen zur bekaempfung von brustkrebs Ceased DE3240044A1 (de)

Priority Applications (9)

Application Number Priority Date Filing Date Title
US05/719,558 US4370321A (en) 1976-09-01 1976-09-01 Progestational adjuvant therapy
AU89358/82A AU558559B2 (en) 1976-09-01 1982-10-14 Progestational adjuvant therapy
CA000413579A CA1205744A (en) 1976-09-01 1982-10-15 Progestational adjuvant therapy
FR8217377A FR2534476B1 (fr) 1976-09-01 1982-10-18 Complement prophylactique a base de 17a-acyloxy-6 methylpregna-4,6-diene-3,20-dione
JP57182210A JPS5973523A (ja) 1976-09-01 1982-10-19 黄体ホルモン含有補助治療剤
BE0/209365A BE894860A (fr) 1976-09-01 1982-10-28 Therapeutique adjuvante par agent progestatif
DE19823240044 DE3240044A1 (de) 1976-09-01 1982-10-28 Verwendung von 17(alpha)-acyloxy-6-methylpregna-4,6-dien-3,20-dionen zur bekaempfung von brustkrebs
GB08231069A GB2129297B (en) 1976-09-01 1982-10-29 Post-mastectomy treatment dosage units containing megestrol acetate
MY8231069A MY8800128A (en) 1976-09-01 1988-12-30 Preparation of post-masectomy treatment medicant

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US05/719,558 US4370321A (en) 1976-09-01 1976-09-01 Progestational adjuvant therapy
AU89358/82A AU558559B2 (en) 1976-09-01 1982-10-14 Progestational adjuvant therapy
CA000413579A CA1205744A (en) 1976-09-01 1982-10-15 Progestational adjuvant therapy
FR8217377A FR2534476B1 (fr) 1976-09-01 1982-10-18 Complement prophylactique a base de 17a-acyloxy-6 methylpregna-4,6-diene-3,20-dione
JP57182210A JPS5973523A (ja) 1976-09-01 1982-10-19 黄体ホルモン含有補助治療剤
BE0/209365A BE894860A (fr) 1976-09-01 1982-10-28 Therapeutique adjuvante par agent progestatif
DE19823240044 DE3240044A1 (de) 1976-09-01 1982-10-28 Verwendung von 17(alpha)-acyloxy-6-methylpregna-4,6-dien-3,20-dionen zur bekaempfung von brustkrebs
GB08231069A GB2129297B (en) 1976-09-01 1982-10-29 Post-mastectomy treatment dosage units containing megestrol acetate

Publications (1)

Publication Number Publication Date
DE3240044A1 true DE3240044A1 (de) 1984-05-03

Family

ID=36764617

Family Applications (1)

Application Number Title Priority Date Filing Date
DE19823240044 Ceased DE3240044A1 (de) 1976-09-01 1982-10-28 Verwendung von 17(alpha)-acyloxy-6-methylpregna-4,6-dien-3,20-dionen zur bekaempfung von brustkrebs

Country Status (9)

Country Link
US (1) US4370321A (enExample)
JP (1) JPS5973523A (enExample)
AU (1) AU558559B2 (enExample)
BE (1) BE894860A (enExample)
CA (1) CA1205744A (enExample)
DE (1) DE3240044A1 (enExample)
FR (1) FR2534476B1 (enExample)
GB (1) GB2129297B (enExample)
MY (1) MY8800128A (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5338732A (en) * 1991-06-18 1994-08-16 Bristol-Myers Squibb Company Megestrol acetate formulation
US6268356B1 (en) 1998-04-20 2001-07-31 Pharmaceutical Resources, Inc. Flocculated suspension of megestrol acetate
US6028065A (en) * 1998-04-20 2000-02-22 Pharmaceutical Resources, Inc. Flocculated suspension of megestrol acetate
US6656505B2 (en) * 2000-07-21 2003-12-02 Alpharma Uspd Inc. Method for forming an aqueous flocculated suspension
ATE469650T1 (de) 2004-12-01 2010-06-15 Par Pharmaceuticals Inc Verwendung von megestrolacetat zur verbesserung der herzfunktion und zur behandlung von herzinsuffizienz

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3356573A (en) * 1958-11-04 1967-12-05 British Drug Houses Ltd 17alpha-acyloxy-6-methylpregna-4, 6-diene-3, 20-diones and method for preparation of these and related 6-methyl-3-oxo-delta4, 6-steroids
US3453297A (en) * 1968-07-24 1969-07-01 Merck & Co Inc 17alpha-lower alkoxy-pregna-4,6-diene-3,20-dione steroids
DE2702509A1 (de) * 1976-01-22 1977-07-28 Leo Ab 17alpha-ester von gestagenen mit antitumor-wirksamkeit, deren herstellung und diese ester enthaltende mittel

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3591689A (en) * 1969-06-04 1971-07-06 Mead Johnson & Co Progestational composition in oral dosage form
ZA716118B (en) * 1970-10-05 1972-05-31 Richardson Merrell Inc Contraception

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3356573A (en) * 1958-11-04 1967-12-05 British Drug Houses Ltd 17alpha-acyloxy-6-methylpregna-4, 6-diene-3, 20-diones and method for preparation of these and related 6-methyl-3-oxo-delta4, 6-steroids
US3453297A (en) * 1968-07-24 1969-07-01 Merck & Co Inc 17alpha-lower alkoxy-pregna-4,6-diene-3,20-dione steroids
DE2702509A1 (de) * 1976-01-22 1977-07-28 Leo Ab 17alpha-ester von gestagenen mit antitumor-wirksamkeit, deren herstellung und diese ester enthaltende mittel

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ANSFIELD, Fred J.: A Clinical Trial of Meges- trol Acetate in Advanced Breast Cancer. In: Cancer 1974, 33, 907-910 *
BRENNAN, Michael J.: Endocrinology in Cancer of the Breast. In: Am. J. Clin. Pathol. 1975, 64, 797-809, insbes. S. 804-5 *

Also Published As

Publication number Publication date
JPS5973523A (ja) 1984-04-25
FR2534476B1 (fr) 1987-07-31
MY8800128A (en) 1988-12-31
US4370321A (en) 1983-01-25
BE894860A (fr) 1983-04-28
AU8935882A (en) 1984-04-19
GB2129297A (en) 1984-05-16
GB2129297B (en) 1986-05-29
AU558559B2 (en) 1987-02-05
CA1205744A (en) 1986-06-10
FR2534476A1 (fr) 1984-04-20
JPH0372605B2 (enExample) 1991-11-19

Similar Documents

Publication Publication Date Title
DE19739916C2 (de) Verwendung einer Kombination aus einem Gestagen und einem Estrogen zur kontinuierlichen Ovulationshemmung und ggf. gleichzeitigen Behandlung und/oder Prophylaxe von Tumoren der Brustdrüsen
DE69434697T2 (de) Therapeutische Verwendungen von Dehydroepiandrosteron zur Behandlung von verminderter Libido und Osteoporose
DE69633405T2 (de) Behandlung von prostatakrebs mit lhrh-antagonisten
DE69125714T2 (de) Zusammensetzung für die behandlung des humanen prostata adenokarzinom
EP0868188B1 (de) Kit zur kontrazeption bei weiblichen säugern, bestehend aus einer kombination von gestagen und estrogen
DE4344462A1 (de) Zusammensetzung für die Empfängnisverhütung
WO1998035682A1 (de) Mittel zur hormonalen kontrazeption und/oder behandlung und/oder prophylaxe von tumoren der brustdrüsen mit drei hormonkomponente
DE60115274T2 (de) Verwendung von antiprogestinen zur prophylaxe und behandlung von hormonabhängigen erkrankungen
DE69323759T2 (de) Verwendung von toremifene für die behandlung von sle
DE3411225C2 (enExample)
DE3240044A1 (de) Verwendung von 17(alpha)-acyloxy-6-methylpregna-4,6-dien-3,20-dionen zur bekaempfung von brustkrebs
DE3916417C2 (enExample)
EP1063998B1 (de) Medikament zur prophylaxe und/oder behandlung des mammarkarzinoms enthaltend einen steroidalen aromataseinhibitor
EP0442350B1 (de) Arzneimittelzubereitung, enthaltend Stigmasta-4-en-3-on sowie deren Verwendung
DE69430356T2 (de) Karzinostatisches Mittel für Hormontherapie, das Dienogest als wirksamer Bestandteil enthält
DD299619A5 (de) Verwendung einer zusammensetzung zur verhinderung von prostatakrebs
WO1998058639A1 (de) Synergistisch wirkende zusammensetzungen zur selektiven bekämpfung von tumorgewebe
DE2811166A1 (de) Arzneimittel, enthaltend trans-broparestrol
DE2401450A1 (de) Pharmazeutische zusammensetzung zur linderung von hautproliferationserkrankungen
DE3827953C2 (enExample)
DE2539824A1 (de) Pharmazeutische zubereitung
WO2014184223A1 (de) Mittel und verfahren zur behandlung von herpes
DE3789173T2 (de) Verwendung von Ketamin zur Herstellung von Arzneimitteln zur Prävention oder Linderung der Effekte von Schlaganfall bei einer Person mit erhöhtem Risiko für Schlaganfall.
DE69610194T2 (de) Mammographieverfahren
DE3721846C2 (enExample)

Legal Events

Date Code Title Description
8110 Request for examination paragraph 44
8127 New person/name/address of the applicant

Owner name: BRISTOL-MYERS SQUIBB CO. (N.D.GES.D.STAATES DELAWA

8128 New person/name/address of the agent

Representative=s name: KINZEBACH, W., DIPL.-CHEM. DR.PHIL. RIEDL, P., DIP

8131 Rejection